VALUE Trial design: Hypertensive patients at high cardiovascular risk were randomized to valsartan (n = 7,649) vs. amlodipine (n = 7,596). Results (p = 0.49) Sudden cardiac death, fatal MI, death during or after PCI or CABG, death due to HF, and death associated with recent MI on autopsy, HF requiring hospitalization, nonfatal MI, or emergency procedures to prevent MI: 10.6% of the valsartan group vs. 10.4% of the amlodipine group (p = 0.49) BP reduction: 17.3 mm Hg with amlodipine vs. 15.2 mm Hg with valsartan (p < 0.0001) 10.6 10.4 % Conclusions Among hypertensive patients at high CV risk, valsartan was not associated with a reduction in cardiac morbidity and mortality compared with amlodipine Lack of benefit for valsartan may be due to greater BP reduction in the amlodipine-based regimen Valsartan Amlodipine Mancia G, et al. Eur Heart J 2015;Nov 20:[Epub]